Silencing of PGK1 Promotes Sensitivity to Paclitaxel Treatment by Upregulating XAF1-Mediated Apoptosis in Triple-Negative Breast Cancer
Objective: Triple negative breast cancer (TNBC) is known to have aggressive clinical course and a high risk of recurrence. Given the lack of effective targeted therapy options, paclitaxel-based chemotherapy is still the primary option for TNBC patients. However, patients who fail to achieve a comple...
Main Authors: | Shanshan Sun, Hao Wu, Xiaohong Wu, Zilong You, Yang Jiang, Xiaoshuan Liang, Zhuo Chen, Ye Zhang, Wei Wei, Yongdong Jiang, Yanbo Chen, Yanni Song, Da Pang |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2021-03-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2021.535230/full |
Similar Items
-
The Discovery of Novel PGK1 Activators as Apoptotic Inhibiting and Neuroprotective Agents
by: Shao-Jia Qiang, et al.
Published: (2022-03-01) -
The oncogenic role and regulatory mechanism of PGK1 in human non-small cell lung cancer
by: Tian Tian, et al.
Published: (2024-01-01) -
Terazosin Stimulates Pgk1 to Remedy Gastrointestinal Disorders
by: Jingjing Liu, et al.
Published: (2021-12-01) -
Expression Characteristics and Significant Prognostic Values of PGK1 in Breast Cancer
by: Yanping Li, et al.
Published: (2021-07-01) -
Prognosis and Immunological Characteristics of PGK1 in Lung Adenocarcinoma: A Systematic Analysis
by: Yuechao Yang, et al.
Published: (2022-10-01)